Please login to the form below

Introduction to the manufacturing of biologics

The last decade has seen the rapid growth of biologics in the pharma market, making them a key sector to watch. With their growing popularity, it’s important to understand the opportunities and threats they present. Associate Consultant Ditte Funding takes us through how biologics are made, what makes them unique, and what it all means for pharma companies.
The last decade has seen the rapid growth of biologics in the pharmaceutical market, making them a key sector to watch in the coming years. Biopharma made up 22% of big pharma companies’ sales in 2013, with this number being expected to rise to 32% of sales by 2023. With the growing popularity of these products, it’s important to understand the opportunities and threats they present to pharma companies.

Associate Consultant Ditte Funding takes us through how biologics are made, what makes them unique, and what it all means for pharma companies.

What is a biologic?

Before looking at how to manufacture them, it’s important to first understand what a biologic is. The definition of a biologic isn’t always clear, and what’s considered a biologic is constantly being updated and tweaked as new products are introduced to market. However, the broad definition of a biologic is they are created by either a microorganism or a mammalian cell, and are large, complex molecules; the majority of which are proteins or polypeptidesExamples of biologics include blood or blood products, gene therapies, vaccines, and cell therapies.

There is a significant distinction that needs to be made between traditional small molecule pharmaceuticals (such as aspirin), and biopharmaceuticals. Biologics differ from small molecule drugs in their cost, production, administration, and clinical efficacy. Small molecule drugs are usually chemically synthesised, simple, and have a very well-defined structure. Whereas biologics, or large molecule drugs, are difficult to define and characterise. 

Biologics present great value, as they are highly specific molecules that tend to target more difficult to treat populations; it seems that biologics may become a primary tool for targeting hitherto untreatable diseases. However, in order for biologics to be widely used treatments in the future, they must be manufactured at the right cost and the right scale.


Download the full article from Blue Latitude Health




17th January 2017

Share

Tags

Company Details

Blue Latitude Health

+44 203 328 1840

Contact Website

Address:
Blue Latitude Health (UK)
140 Aldersgate Street
London
EC1A 4HY
United Kingdom

Latest content on this profile

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance treatment and improve patient and stakeholder outcomes.
Blue Latitude Health
The changing face of pharma in the precision era
Blue Latitude Health speaks to Nancy Brandt, a Senior Leader in Global Medical Information at a top 20 biopharma organisation. Here, she reveals what pharmaceutical companies need to do to prepare to bring precision medicines to market and how she is ensuring the patient is consulted every step of the way.
Blue Latitude Health
Creative problem solving, solved
Customer Experience Consultant Eimear Power explains how pharma teams can unlock their creativity and foster truly innovative ideas.
Blue Latitude Health
Three strategies for managing loss of exclusivity successfully
Claire Taylor, Senior Associate Consultant at Blue Latitude Health explains why you should be strategically planning your LOE strategy years in advance.
Blue Latitude Health
Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to make a more accurate treatment decision. Here we discuss the barriers, opportunities and potential outcomes of the precision medicine era in healthcare.
Blue Latitude Health
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist and Director of Public Health at Genomics England, to find out how the NHS is achieving this goal.
Blue Latitude Health